Development and Evaluation of Novel Surfactant-Based Elastic Vesicular System for Ocular Delivery of Fluconazole

Kaur, Indu Pal; Rana, Cheena; Singh, Manjit; Bhushan, Shashi; Singh, Harinder; Kakkar, Shilpa

doi:10.1089/jop.2011.0176

Cited by 77 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ocular formulation should release the drug by bypassing the protective barriers of the eye without damaging the tissues (Ali et al, 2016). Ocular drug delivery systems generally have low bioavailability, limited absorption in the intraocular area due to blinking reflex, less eye capacity, nasolacrimal drainage, and the corneal and conjunctival epithelial barriers which ultimately reduces the retention time of drug molecules in the eyes (Kaur et al, 2012). Thus, frequent instillations of eye drops are usually required in clinical systems to attain anticipated therapeutic effectiveness which leads to patient noncompliance, tissue damage, and other toxic effects integrated with nasolacrimal absorption (Luo et al, 2011).…”

Section: Ocular Deliverymentioning

confidence: 99%

Proniosomes derived niosomes: recent advancements in drug delivery and targeting

et al. 2017

View full text Add to dashboard Cite

Vesicular drug delivery systems have gained wide attention in the field of nanotechnology. Among them proniosomes become the superior over other vesicular carriers. Proniosomes are dry formulations of water soluble nonionic surfactant coated carrier system which immediately forms niosomes upon hydration. They have the capability to overcome the instability problems associated with niosomes and liposomes and have the potential to improve solubility, bioavailability, and absorption of various drugs. Furthermore, they offer versatile drug delivery concept for enormous number of hydrophilic and hydrophobic drugs. They have the potential to deliver drugs effectively through different routes at specific site of action to achieve controlled release action and reduce toxic effects associated with drugs. This review discusses the general preparation techniques of proniosomes and mainly focus on the applications of proniosomes in drug delivery and targeting. Moreover, this review demonstrates critical appraisal of the literature for proniosomes. Additionally, this review extensively explains the potential of proniosomes in delivering drugs via different routes, such as oral, parenteral, dermal and transdermal, ocular, oral mucosal, vaginal, pulmonary, and intranasal. Finally, the comparison of proniosomes with niosomes manifests the clear distinction between them. Moreover, proniosomes need to be explored for proteins and peptide delivery and in the field of nutraceuticals and develop pilot plant scale up studies to investigate them in industrial set up. ARTICLE HISTORY

show abstract

Section: Ocular Deliverymentioning

confidence: 99%

Proniosomes derived niosomes: recent advancements in drug delivery and targeting

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, traditional ocular drug delivery systems have a lower bioavailability, due to the limited eye capacity, blinking reflex, lachrymal fluid erosion, nasolacrimal drainage, and the biological barrier of the corneal and conjunctival epithelia, which reduce the amount of effective drug, shorten the retention time in the eyes and produce less absorption in the intraocular area [2]. Therefore, in clinical applications, frequent instillations of eye drops are often required to obtain the expected therapeutic efficacy, which may lead to problems with patient compliance, cellular damage and other side effects associated with nasolacrimal absorption [3].…”

Section: Introductionmentioning

confidence: 99%

“…Deformable liposomes (DL), as a special form of liposomes, have many favorable properties. DL consists of phospholipids and edge activators (surfactants with a high radius of curvature and mobility) [16], and a higher degree of penetration of the mucous membrane compared with conventional liposomes (CL) as has been proved in many studies of their ophthalmic use [2,12]. In addition, DL are highly deformable and/or flexible and can cross pores of a size smaller than the conventional liposomal diameter without disassembling, because the lipid bilayers are affected by edge activators and exhibit a higher curvature [13].…”

Section: Introductionmentioning

confidence: 99%

The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system

Chen

Pan

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…Another non-conventional type of niosomes called spanlastic vesicles has been recently studied for ocular administration. Spanlastic vesicles (SV) composed of Span 60 and Tween 80 (edge activator) in nano-sized ranges demonstrated deformability/elasticity and enhanced ocular bioavailability compared with conventional niosomes (Kakkar & Kaur, 2011;Kaur et al, 2012). However, these SVs did not contain cholesterol (a bilayer membrane stabilizer) which might impose physical instability problems such as drug leakage and vesicle aggregations with aging (storage).…”

Section: Introductionmentioning

confidence: 99%

Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone

Gaafar

Abdallah

Farid

et al. 2014

Journal of Liposome Research

View full text Add to dashboard Cite

Niosomes embodying ethanol and minimum amount of cholesterol (ethoniosomes) could be promising ocular delivery systems for water soluble and insoluble drugs. This manuscript reports on novel nano-sized elastic niosomes (ethoniosomes) composed of Span 60: cholesterol (7:3 mol/mol) and ethanol, for ocular delivery of prednisolone acetate (Pred A) and prednisolone sodium phosphate (Pred P). These ethoniosomes were prepared with the thin film hydration (TFH) and ethanol injection (EI) methods, characterized for percentage entrapment efficiency (% EE), size, zeta potential, morphology, elasticity, in vitro release and physical stability. Ocular irritation, bioavailability and anti-inflammatory effects were evaluated and compared with the conventional suspension and solution eye drops. The prepared ethoniosomal vesicles (EV) had a Z-average diameter of 267 nm, zeta potential of approximately -40 mV and % change in size after extrusion of 4%. They were physically stable for at least 2 months at 4 °C. The prepared EV showed good ocular tolerability using the modified Draize's test and the estimated relative ocular bioavailability for Pred A EV and Pred P EV was 1.54 and 1.75 times greater than that for the suspension and solution eye drops, respectively. The time required for complete healing from the clove oil-induced severe ocular inflammation was reduced to half with Pred A and Pred P EV. More interestingly, the intraocular pressure (IOP) elevation side effect recorded for Pred A and Pred P EV was significantly less than that for the conventional suspension and solution eye drops.

show abstract

Development and Evaluation of Novel Surfactant-Based Elastic Vesicular System for Ocular Delivery of Fluconazole

Abstract: The developed system is novel and provides an effective and safe formulation of fluconazole.

Cited by 77 publications

References 39 publications

Proniosomes derived niosomes: recent advancements in drug delivery and targeting

Proniosomes derived niosomes: recent advancements in drug delivery and targeting

The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system

Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone

Contact Info

Product

Resources

About